BCG-Unresponsive NMIBC: Radical Cystectomy vs Bladder-Sparing Therapy

Authored by Natalia Gandur, published on 2026-05-28 20:49:01.0

In a patient with high-risk BCG-unresponsive NMIBC, who should proceed to early radical cystectomy and who is a reasonable candidate for bladder-sparing therapy?This should not be a broad NMIBC algorithm. It should begin only after the clinician has already confirmed that the patient has high-risk NMIBC after adequate BCG exposure and now needs a definitive post-BCG decision.

  1. Patient with High-Risk NMIBC after Prior BCG
    • Confirm Current Disease Status
      Pathology review (confirm high grade) CIS vs papillary disease Ta vs T1 Muscle in specimen Variant histology Lymphovascular invasion Repeat TURBT if indicated Upper tract evaluation Prostatic urethral evaluation Imaging if indicated Exclude MIBC or metastasis
      • Confirm BCG Exposure Category
        Does the patient meet BCG-unresponsive criteria after adequate BCG?
        • NO - patient does not meet BCG-unresponsive criteria after adequate BCG
          BCG-exposed / Delayed relapse / Intolerant pathway (may benefit from additional BCG in selected cases).
        • YES - patient does meet BCG-unresponsive criteria after adequate BCG
          BCG-UNRESPONSIVE HIGH-RISK NMIBC.
          • Review patient for highest-risk features
            T1 high-grade recurrence Variant histology LVI Prostatic urethral involvement Multifocal/bulky high-grade disease Rapid recurrence after BCG Prior bladder-sparing failure
            • Cystectomy Fitness & Patient Preference
              Is the patient fit and willing for radical cystectomy? Yes if: Surgically fit Understands benefits/risks Willing to undergo cystectomy No if: Unfit for surgery Declines cystectomy Prefers bladder preservation
              • YES
                Surgically fit Understands benefits/risks Willing to undergo cystectomy
                • RADICAL CYSTECTOMY FAVORED
                  Oncologic benchmark for durable disease control
              • NO / DECLINES
                Unfit for surgery Declines cystectomy Prefers bladder preservation
                • BLADDER-SPARING THERAPY OR CLINICAL TRIAL
                  • Select Bladder-Sparing Approach by Disease Phenotype
                    • CIS with or without papillary tumors
                      Pembrolizumab (IV) Nadofaragene firadenovec (intravesical) Nogapendekin alfa inbakicept (NAI) + BCG (intravesical) Intravesical chemotherapy (e.g., gemcitabine/docetaxel) Clinical trial
                      • Response Assessment & Surveillance
                        Cystoscopy Urine cytology Biopsy as indicated Upper tract evaluation as indicated Prostatic urethral evaluation as indicated Timing per protocol/therapy-specific guidance Typical early assessment at 3 months, then every 3 months in year 1–2, every 6 months in year 3–5, then annually (adjust per risk and protocol).
                        • Stopping Rules => proceed to cystectomy (if fit) or MIBC pathway if progressed
                          Stop if: Persistent high-grade disease after adequate assessment Persistent CIS High-grade recurrence T1 high-grade recurrence Progression to MIBC Prostatic urethral or upper tract progression Unacceptable toxicity Repeated recurrence after bladder-sparing therapy Inability to comply with surveillance Patient would not accept salvage cystectomy if needed
                    • Papillary-only Ta/T1 high-grade
                      Complete TURBT Intravesical chemotherapy (gemcitabine/docetaxel) Consider nadofaragene or NAI + BCG if indication & availability appropriate Clinical trial Radical cystectomy if highest-risk & fit
                      • Response Assessment & Surveillance
                        Cystoscopy Urine cytology Biopsy as indicated Upper tract evaluation as indicated Prostatic urethral evaluation as indicated Timing per protocol/therapy-specific guidance Typical early assessment at 3 months, then every 3 months in year 1–2, every 6 months in year 3–5, then annually (adjust per risk and protocol).
                        • Stopping Rules => proceed to cystectomy (if fit) or MIBC pathway if progressed
                          Stop if: Persistent high-grade disease after adequate assessment Persistent CIS High-grade recurrence T1 high-grade recurrence Progression to MIBC Prostatic urethral or upper tract progression Unacceptable toxicity Repeated recurrence after bladder-sparing therapy Inability to comply with surveillance Patient would not accept salvage cystectomy if needed
      • MIBC or Metastatic Disease
        EXIT to MIBC / Advanced UC Pathway
tosprivacy